- Fellowship - University of Calfornia - San Francisco (2000-2003), Neuro-oncology
- Residency - Tufts University Neurology Residency Program (1997-2000), Neurology
- Internship - The Cambridge Hospital (1996-1997), Transitional Year
- Medical School - Boston University School of Medicine (1990-1996)
Edward Pan, M.D.
- Medical Treatment of Brain & Spinal Cord Cancer
Cancer scares many people, even doctors, but it doesn’t faze Edward Pan, M.D. Growing up near Valparaiso, Ind., he knew early on that he wanted to be a doctor; his father was a family physician who often brought his son to the office.
Dr. Pan majored in medical sciences at Boston University, where he also earned his medical degree. He did his internship at Harvard and his neurology residency at Tufts.
As a neurology resident doing consultations for other doctors, Dr. Pan grew interested in the ins and outs of brain cancer and decided to do a fellowship in clinical neuro-oncology at the University of California, San Francisco (UCSF).
After two additional years at UCSF as a research fellow, Dr. Pan went on to care for brain cancer patients at UCSF, Florida Hospital Cancer Institute, and MD Anderson Cancer Center in Orlando. He spent the five years before coming to UT Southwestern working as a neuro-oncologist at Moffitt Cancer Center in Tampa and taught neurology and oncology at the University of South Florida School of Medicine and the Moffitt Cancer Center.
In 2013, he joined the UT Southwestern faculty as Assistant Professor in the Department of Neurology and Neurotherapeutics.
Dr. Pan is a highly experienced clinical researcher, having been the principal or sub-investigator in numerous trials of cancer drugs for malignant brain tumors. Among many other subjects, he has researched chromosomal abnormalities in brain cancer. In addition, he has published his results in peer-reviewed journals and authored four book chapters.
Meet Dr. Pan
Brain tumor specialist Edward Pan, M.D., is an expert in translational medicine – a fast-growing approach to cancer care in which doctors and lab researchers put their heads together to get new ideas off the ground and fast-track lab findings into innovative treatment options. Where more traditional methods can be slow to benefit patients, translational medicine calls for physicians who are comfortable speaking the “languages” of lab work, clinical research, and patient care, which can speed up results.
“Any neuro-oncologist understands that quality of life is the most important measure. In clinical trials, we try to improve quality of life, or at least extend reasonable quality of life for as long as possible.”
Trained in neuro-oncology and experienced in working with lab researchers as a veteran investigator in dozens of clinical trials, Dr. Pan is ideally suited for the job. He works with fellow neuro-oncologist Elizabeth Maher, M.D., Ph.D. to study promising new approaches to treating brain tumors.
“Our neuro-oncologists here have a very productive lab,” Dr. Pan says. “My goal is to partner with these cutting-edge brain tumor lab researchers to do both lab and clinical research.”
He adds that he is constantly on the lookout for trials that could benefit brain tumor patients, such as studies of vaccines that could teach a patient’s immune system to destroy the cancer.
Dr. Pan is part of UT Southwestern’s multidisciplinary brain tumor team, which includes neuro-oncologists, neurosurgeons, radiation oncologists, neuropathologists, and neuroradiologists. Every week, this group of experts meets to discuss recommendations for patients with cancers of the brain, such as glioblastoma multiforme.
Thanks in part to Dr. Pan’s translational expertise, the team can draw upon new ideas from lab research, and patients are often found to be eligible for a clinical trial.
“Brain tumors occur much less frequently compared to other cancers,” says Dr. Pan. “Therefore, if you have a brain tumor, you want brain tumor experts who deal with such cases all the time and who have a lot of experience handling the neurologic complications of these tumors.”
- American Academy of Neurology (1998)
- Society for Neuro-Oncology (2002)
- American Society of Clinical Oncology (2004)
Glioma: Symptoms, Diagnosis and Treatment Options
Ashraf N, Pan E(Ed.) (2013), Hauppauge, New York, Nova Science
Pediatric Central Nervous System Tumors
Pan E, Prados M(Ed.) (2004), Berlin, Germany, Springer-Verlag
Holland-Frei Cancer Medicine e.6
Pan E, Prados M(Ed.) (2003), Toronto, Canada, BC Decker
Pan E, Uyehara-Lock J, Nicholas MK(Ed.) (2002), Toronto, Canada, BC Decker
- Glioma: Symptoms, Diagnosis and Treatment Options
Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients.
Pan E, Pellarin M, Holmes E, Smirnov I, Misra A, Eberhart CG, Burger PC, Biegel JA, Feuerstein BG Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Jul 11 13 4733-40
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma.
Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, Yung WK, Feuerstein BG, Aldape KD Cancer research 2005 Mar 65 5 1678-86
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Pan E, Mitchell SB, Tsai JS Journal of neuro-oncology 2008 Jul 88 3 353-7
Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients.
Pan E, Tsai JS, Mitchell SB Anticancer research 2009 Oct 29 10 4309-13
Poor drug distribution as a possible explanation for the results of the PRECISE trial.
Sampson JH, Archer G, Pedain C, Wembacher-Schröder E, Westphal M, Kunwar S, Vogelbaum MA, Coan A, Herndon JE, Raghavan R, Brady ML, Reardon DA, Friedman AH, Friedman HS, Rodríguez-Ponce MI, Chang SM, Mittermeyer S, Croteau D, Puri RK Journal of neurosurgery 2010 Aug 113 2 301-9
Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis.
Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S Journal of the National Comprehensive Cancer Network : JNCCN 2011 Apr 9 4 403-7
Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide.
Devito N, Yu M, Chen R, Pan E Anticancer research 2011 Dec 31 12 4537-43
Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.
Chinnaiyan P, Chowdhary S, Potthast L, Prabhu A, Tsai YY, Sarcar B, Kahali S, Brem S, Yu HM, Rojiani A, Murtagh R, Pan E Neuro-oncology 2012 Jan 14 1 93-100
A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma.
Pan E, Yu D, Yue B, Potthast L, Chowdhary S, Smith P, Chamberlain M Journal of neuro-oncology 2012 Oct 110 1 111-8
Control of brain metastases for HER2-positive breast cancer with bevacizumab: a report of three patients
Sajjad M, Pan E, Minton S, Ismail-Khan R Journal of Solid Tumors 2013 3 4 1-6
Predictors of Survival, Neurologic Death, Local Failure, and Distant Failure after Gamma KnifeTM Radiosurgery for Melanoma Brain Metastases.
Neal MT, Chan MD, Lucas JT, Loganathan A, Dillingham C, Pan E, Stewart JH, Daniel Bourland J, Shaw EG, Tatter SB, Ellis TL World neurosurgery 2013 Feb
Anthropometric factors in relation to risk of glioma.
Little RB, Madden MH, Thompson RC, Olson JJ, Larocca RV, Pan E, Browning JE, Egan KM, Nabors LB Cancer causes & control : CCC 2013 Mar
Early life exposures and the risk of adult glioma.
Anic GM, Madden MH, Sincich K, Thompson RC, Nabors LB, Olson JJ, Larocca RV, Browning JE, Pan E, Egan KM European journal of epidemiology 2013 May
Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center.
Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M International journal of hematology 2014 Apr 99 4 450-6
Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors.
Pan E, Yu D, Zhao X, Neuger A, Smith P, Chinnaiyan P, Yu HH Journal of neuro-oncology 2014 Jun
In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma.
Sagiyama K, Mashimo T, Togao O, Vemireddy V, Hatanpaa KJ, Maher EA, Mickey BE, Pan E, Sherry AD, Bachoo RM, Takahashi M Proceedings of the National Academy of Sciences of the United States of America 2014 Mar 111 12 4542-7
- Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients.
- Medical Treatment of Brain & Spinal Cord Cancer
- Brain & Spinal Cord Cancer
Q&A by Dr. Pan
Showing 1 locations